Lexicon Pharmaceuticals
LXRX
107 hedge funds and large institutions have $710M invested in Lexicon Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 29 increasing their positions, 29 reducing their positions, and 26 closing their positions.
90% more call options, than puts
Call options by funds: $2.58M | Put options by funds: $1.35M
70% more capital invested
Capital invested by funds: $417M → $710M (+$293M)
12% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 26
1% more funds holding
Funds holding: 106 → 107 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 29
2.25% less ownership
Funds ownership: 86.24% → 83.99% (-2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$8.4M |
| 2 |
BlackRock
New York
|
+$6.72M |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
+$6.36M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.57M |
| 5 |
Two Sigma Investments
New York
|
+$3.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$17.8M |
| 2 |
Morgan Stanley
New York
|
-$9.52M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$8.53M |
| 4 |
Millennium Management
New York
|
-$5.16M |
| 5 |
Renaissance Technologies
New York
|
-$4.73M |
LXRX Hedge Fund Activity: Q1 2021 in Review
107 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q1 2021, worth a combined $710M — up 70% from $417M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new LXRX positions and 26 closed out — a net gain of 3 holders — while 29 added to existing stakes and 29 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $8.4M. The largest seller was BVF Inc, cutting an estimated $17.8M.
- 107 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q1 2021, up from 106 in Q4 2020.
- Funds reported $710M of Lexicon Pharmaceuticals stock for Q1 2021, up 70% quarter-over-quarter.
- 29 funds opened new Lexicon Pharmaceuticals positions in Q1 2021 and 26 closed out, a net change of +3 holders.
- The largest Lexicon Pharmaceuticals buyer in Q1 2021 was D.E. Shaw & Co, an estimated $8.4M added.
- The largest Lexicon Pharmaceuticals seller in Q1 2021 was BVF Inc, an estimated $17.8M sold.
Based on aggregated 13F filings for Q1 2021.